Agios Pharmaceuticals
$46.55
20
-$0.83-1.75% 今天
統計
當日最高
47.7
當日最低
46.49
52週最高
50.35
52週最低
19.8
成交量
938,926
平均成交量
490,687
市值
2.61B
市盈率
-
股息收益率
-
股息
-
即將到來
收益
31Oct預期
預期每股收益
-1.710352
實際每股收益
N/A
人們還關注
此列表基於在 Stock Events 上關注 AGIO 的人的關注列表。這不是投資建議。
競爭者
這個列表是基於最近市場事件的分析。這不是投資建議。
Bluebird bio
BLUE
市值108.22M
CRISPR Therapeutics
CRSP
市值4.06B
Vertex Pharmaceuticals
VRTX
市值127.99B
Gilead Sciences
GILD
市值98.35B
AMGEN
AMGN
市值179.38B
Biomarin Pharmaceutical
BMRN
市值17.36B
Sangamo Therapeutics
SGMO
市值176.57M
Novartis
NVS
市值244.75B
Alnylam Pharmaceuticals
ALNY
市值33.72B
Beam Therapeutics
BEAM
市值2.2B
分析師評級
51.33$平均價格目標
最高估價為 $55。
來自過去 6 個月內的 4 個評級。這不是投資建議。
買入
50%
持有
50%
賣出
0%
關於
Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Show more...
首席執行官
Jacqualyn Fouse
員工
383
國家
US
ISIN
US00847X1046